🌟 Lumakras Breakthrough: Amgen (AMGN) pioneers cancer treatment with Lumakras, the first medication targeting a mutation found in approximately 13% of lung cancer patients.
💰 Strategic Acquisition: Amgen acquires Horizon Therapeutics for a substantial $28 billion in cash. Incorporates Tepezza, an FDA-approved medicine for thyroid eye disease, into Amgen's product portfolio.
📈 Market Outlook: Bullish stance on AMGN suggests support levels above $260.00-$265.00. Anticipated upside target in the range of $360.00-$365.00.
Exciting developments in biotech and strategic expansion for Amgen! 🌐💉